Antivirals against Arboviruses

Dear Colleagues,

There are more than 100 arthropod-borne viruses or arboviruses that are causative agents of infections and diseases in humans and animals. A significant subset, including members of the Flaviviridae (e.g., dengue and Zika virus), Bunyaviridae (e.g., Rift Valley fever virus), and Togaviridae (e.g., chikungunya virus) families, are considered medically important viral pathogens responsible for significant morbidity and mortality worldwide. Furthermore, with changes in global temperature and the spread of arthropod vectors, the emergence and re-emergence of arbovirus infections in more temperate regions have led to increased infection rates and to more people with severe diseases.

Despite the significant global burden of arbovirus infections, there are no approved antiviral agents available for the therapy of arbovirus infections. Though some small-molecule compounds have been identified as inhibitors against some arboviruses, most of them have not advanced into clinical trials. Considering the clinical significance and global impact of arbovirus infections, efforts to develop anti-arboviral drugs are urgently needed, and this field is attracting increasing attention worldwide.

This Special Issue of Viruses aims to highlight recent progress in the research and development of novel antivirals against arboviruses. We also aim to provide a forum to present new antiviral strategies for fighting off arbovirus infections.

Dr. Benjamin M. Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.